What is the clinical evidence from this study?

Study design: Review. Population: Atrial Fibrillation. Intervention: Dronedarone vs. control.

What question did this study set out to answer?

The aim is to summarize the clinical development and efficacy of dronedarone for atrial fibrillation treatment.

May 14, 2010Journal of Cardiovascular Pharmacology and Therapeutics

Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials

View Full Paper

Ask AI

Bookmark

Key result

Dronedarone prolonged time to first atrial fibrillation recurrence and reduced cardiovascular hospitalization or death in >4600 patients with nonpermanent atrial fibrillation.

Why the study?

Does dronedarone reduce cardiovascular hospitalization or death and prolong time to AF recurrence in patients with atrial fibrillation?

Key Points

The aim is to summarize the clinical development and efficacy of dronedarone for atrial fibrillation treatment.
Analyzed data from phase II and phase III trials, including DAFNE, EURIDIS, and ADONIS studies.
Evaluated dronedarone 400 mg twice daily for maintenance of sinus rhythm in patients with atrial fibrillation and flutter.
Conducted a large randomized trial involving over 4600 patients to assess cardiovascular hospitalization and mortality.
Dronedarone significantly prolonged the mean time to first AF/flutter recurrence.
Increased incidence of primary endpoint (CV hospitalization or death), with significant reduction in cardiovascular mortality specifically.
The drug was deemed safe in the majority of studies, but had issues in patients with severe heart failure.

Structured PICO

Does dronedarone reduce cardiovascular hospitalization or death and prolong time to AF recurrence in patients with atrial fibrillation?

Population

Review of clinical trials evaluating dronedarone for the treatment of atrial fibrillation and maintenance of sinus rhythm.

Intervention

Dronedarone (400 mg twice-daily dosing)

Comparator

Control group

Outcome

Time to first AF/flutter recurrence; time to first cardiovascular hospitalization or deathcomposite

Dronedarone is effective for maintaining sinus rhythm and reducing cardiovascular hospitalization or death in patients with nonpermanent AF, but is associated with excess mortality in patients with severe congestive heart failure.

Limitations

Excess mortality in patients with severe congestive heart failure

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support dronedarone for nonpermanent AF; leaves open optimal selection excluding severe heart failure.

Cite This Study

Duray et al. (2010) conducted a review in Atrial Fibrillation. Dronedarone vs. control was evaluated. Dronedarone prolonged time to first atrial fibrillation recurrence and reduced cardiovascular hospitalization or death in >4600 patients with nonpermanent atrial fibrillation.

synapsesocial.com/papers/6a39cd7bc5135fa86afa1e40 https://doi.org/10.1177/1074248410368530

Topics

Persistent AF management Atrial fibrillation Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Topics

Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider